Asahi Kasei Medical
  • Site Map
  • Contact Us
  • Font size: Small
  • Font size: Medium
  • Font size: Large
  • Home
  • Our Approach to Business
  • Corporate Information
  • News
  • Products
  • Patients and Families

June 16, 2010
Asahi Kasei Kuraray Medical Co., Ltd.

Corporate

New development in blood-related business
Amendment to license agreement for autologous fibrin sealant producing system

Asahi Kasei Kuraray Medical and ThermoGenesis Corp. have concluded an amendment to the Distribution and License Agreement for ThermoGenesis’s CryoSeal® FS System, which they entered into in May 2005.

Through this amendment, in addition to the existing rights to sell the CryoSeal® FS System in Japan, Asahi Kasei Kuraray Medical obtained exclusive rights to manufacture the system in Japan and to sell it in certain Asian countries. Furthermore, Asahi Kasei Kuraray Medical obtained exclusive rights for the future purchase of intangible assets, including intellectual property rights, related to the system.

While advancing the process of obtaining marketing approval from the Japanese authorities, Asahi Kasei Kuraray Medical will begin transferring manufacturing technology of the CryoSeal® FS System from ThermoGenesis in order to provide safe treatment to patients and a highly efficient system to hospitals as soon as possible.

Profile of ThermoGenesis Corp.

CEO: J. Melville Engle
Location: Rancho Cordova, California, USA
Establishment: 1986 (Nasdaq listed 1987)
Sales: US$19.8 million
Employees: ≈80
Main business: Stem cell-related business

About the CryoSeal® FS System

The CryoSeal® FS System, comprising an automated device and companion sterile blood processing disposables, is used to prepare fibrin sealants from plasma in about an hour. A fibrin sealant is a clotting agent composed of fibrinogen and thrombin used in combination with proteins, and fibrin sealants are typically used by surgeons during procedures where there is substantial bleeding. The most outstanding advantage of the CryoSeal® FS System is that it can produce autologous fibrin sealant which provides the highest level of safety for patients. The CryoSeal® FS System is approved in the US for liver resection surgeries, and has received the CE Mark which allows its sale throughout the European Union.

Top of page